SALMA VELAZQUEZ: Open Payments
NPI 1558755728 · LEAWOOD, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,374 in 83 payments from 16 companies in 2025. Trend: 2023 $1,657 · 2024 $1,366 · 2025 $1,374
Food & beverage: $1,374
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $218 |
| Otsuka America Pharmaceutical, Inc. | 13 | $183 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $165 |
| Neurocrine BioSciences, Inc. | 6 | $117 |
| Lundbeck LLC | 5 | $113 |
| Supernus Pharmaceuticals, Inc. | 6 | $110 |
| Axsome Therapeutics, Inc. | 5 | $90 |
| Janssen Pharmaceuticals, Inc | 5 | $85 |
| Collegium Pharmaceutical, Inc. | 4 | $76 |
| Vanda Pharmaceuticals Inc. | 3 | $58 |
Products named: REXULTI, VRAYLAR, CAPLYTA, INGREZZA, Qelbree, SPRAVATO, Jornay PM, Auvelity.
Industry payments across KS — which companies pay providers there.
